Latest News Archive

Please select Category, Year, and then Month to display items

Campaign raises hearing loss and Deaf awareness

07 October 2024 | Story André Damons | Photo Supplied

Deaf awareness Campaign 2024 — Boipelo Leteane, Amahle Jemane, Zinzile Sibiya (Speech-Language Pathologist at UAH), Ntsatsi Dingaan-Mokushane, Andani Madzivhandila, Yolanda Nzume (Administration Clerk at UAH) and Dr Phindile Shangase at the Deaf Awareness Campaign at the UFS.

The Department of Speech Therapy and Audiology at Universitas Academic Hospital (UAH), in partnership with the Division of Public Health at the University of the Free State (UFS) recently held their annual Deaf Awareness Campaign with much success.

The campaign, which is the brainchild of Andani Madzivhandila, a Cochlear Implant MAPping Audiologist at Universitas Academic Hospital (UAH), is in its second year and was attended by Deaf students from the UFS, community members and academics from the UFS Faculty of Health Sciences, including Dr Phindile Shangase from the Division of Public Health at the UFS in collaboration with UAH Speech Therapy and Audiology staff.

Purpose of the event

The event took place on 28 September 2024 in the foyer of the Francoise Retief building. September is the International Month for Deaf People. The Department of Otorhinolaryngology and Med-EL assisted with some sponsorship to make the event a success. Ntsatsi Dingaan-Mokushane, the Assistant Director for Speech Therapy and Audiology at UAH, opened the ceremony and highlighted the importance of Deaf Awareness Campaigns in general and further elaborated on the World Federation of the Deaf theme for 2024, which is “Sign up for sign language rights”.

Dr Shangase shared her experiences and challenges of living with hearing loss and how she manages it, and further elaborated that the purpose of the event was to raise awareness of the different types of hearing loss, especially deafness. It was also to raise awareness of the challenges encountered by Deaf people and to discuss available technologies to assist those with hearing loss as well as those who are born profoundly Deaf.

The event is organised to share experiences from professionals, those with hearing loss as well as the Deaf community, to share experiences on coping and managing life with hearing loss as well as deafness. The organisers try to educate the public about Deaf culture, sign language and the experiences of Deaf people and to help combat stereotypes, stigmas and misconceptions surrounding deafness. The event is also to promote inclusion and encourage equal access to education, employment, healthcare as well as breaking down communication barriers and address systemic and social barriers that hinder Deaf individuals’ participation.

Sharing lived experiences

According to Dr Shangase, the event highlighted the progress as well as gaps in support interventions for those who live with hearing loss and deafness. Says Dr Shangase: “Availability of technologies was highlighted as facilitating different forms of participation for those with hearing loss and deafness. However, it was clear that most of the available technologies are not being adopted in workplaces as well as in communities.”

Boipelo Leteane, a parent of a two-year-old child who was born deaf, shared her experiences and her journey before and after her child had undergone a cochlear implant, while Madzivhandila shed some light on the challenges faced by healthcare professionals when hearing loss/deafness is diagnosed and needs to be managed.

Amahle Jemane also shared her personal experiences and challenges she faces daily as a signing young female in South Africa, where the majority of the population use spoken language, and she uses South African Sign Language (SASL).

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept